<!Doctype html>
<html lang="en">
  <head>
	<meta name="generator" content="Hugo 0.55.5" />
    
      <meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta http-equiv="x-ua-compatible" content="ie=edge" />
<link rel="icon" type="image/x-icon" href="/images/favicon.ico">
<title>Dosing Schedule</title>


<link href="https://fonts.googleapis.com/css?family=Roboto:300,400,500,700,900" rel="stylesheet">
<link rel="stylesheet" href="/css/jquery-ui.css/" />
<link rel="stylesheet" href="/css/bootstrap.min.css/" />
<link rel="stylesheet" href="/css/site.min.css" />


    

    
      <style>
  @page { margin: 0mm; }
  @media print {
    main {
      margin: 20px auto;
    }
    .chart-img{
      width: 600px;
      margin: 0 auto;
    }
    .header-title{
      -webkit-print-color-adjust: exact; 
      background-color: #00A5E0 !important;
    }
    .header-title>h3{
      font-size: 16px;
      font-weight: bold;
    }
    .header-title sup {
      font-size: 10px;
    }
    .dose-schedule-btn{
      display: none; 
    }
    .schedule-picker>.picker{
      width: 180px;
      height: 180px;
      line-height: 180px;
      -webkit-print-color-adjust: exact; 
      background-image: url(/images/picker.png);
    }
    .ui-datepicker-trigger{
      width: 50px;  
      height: 50px;  
    }
    .step-arrow{
      width: 60px;
      height: 60px;
      margin-left: 0;
      margin-right: 0;
      -webkit-print-color-adjust: exact;
      background-image: url(/images/Forma.png);
    }
    .dose-end-text{
      display: none;
    }
    .schedule-picker>h3 {
      margin-top: -55px;
    }
    .skyrizi-logo{
      display: block;
    } 
    .top-date {
      top: 70px;
    }
    .left-date {
      top: 285px;
      left: 55px;
    }
    .right-date {
      top: 285px;
      right: 50px;
    }
    .bottom-date {
      bottom: 70px;
      left: 280px;
    }
    .print-only{
      display: block;
    }
    #picked_date{
      line-height: 172px;
    }
  }
</style>

    
  </head>
  <body>
    <div class="container">
        <div class="row">
            <div class="col-sm-12">
              <main>
                <ul>
  
    <li><a href="/">English</a></li>
  
    <li><a href="/fr/">Français</a></li>
  
</ul>
      
                
  <div class="dose-schedule">
    <div class="header-title">
      <h3>SKYRIZI<sup>TM</sup> (risankizumab) Practice Dosing Schedule for the Last Year</h3>
    </div>
  
    <div class="dose-schedule-cmp">
      <div class="schedule-picker">
        <h3>Start</h3>
        <div class="picker">
          <p id="picked_date"></p>
          <input type="hidden" id="dp" />
        </div>
        <p class="dose-end-text">End date<br>of 1st dose</p>
      </div>
      <div class="step-arrow">
        &nbsp;
      </div>
      <div class="dose-schedule-chart">
        <img class="chart-img" src="/images/chart.png" alt="">
        <div class="dose-count">
          <h1>04</h1>
          <p>Doses</p>
        </div>
        <p class="left-date">
          <span class="desk-view">29 Jan</span>
          <span class="mobile-view">08 Oct</span>
        </p>
        <p class="top-date">
          <span class="desk-view">23 Apr</span>
          <span class="mobile-view">29 Jan</span>
        </p>
        <p class="right-date">16 Jul</p>
        <p class="bottom-date">8 Oct</p>
      </div>
      <button onclick="printFunction()" class="btn dose-schedule-btn">Click to Print</button>
      <img class="skyrizi-logo" src="/images/skyrizi.png" alt="">
    </div>
  </div>

  <div class="footer-area">
    <ul>
<li>SKYRIZI is dosed 150 mg (two 75-mg subcutaneous injections) at Week 0, Week 4, and every 12 weeks thereafter.1</li>
<li>SKYRIZI doses continue every 12 weeks after the first 5 doses shown above. It is important for patients to
take their treatment as prescribed to achieve the full benefit. If patients stop treatment, their symptoms may
come back.</li>
<li>Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks
of treatment. Some patients with initial partial response may subsequently improve with continued treatment
beyond 16 weeks.</li>
<li>If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at
the regular scheduled time.</li>
</ul>
    <div class="print-only">
      <hr />
      <p class="mb-0"><b>Indication</b></p>
      <p>Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults
  who are candidates for systemic therapy.</p>
      <p class="mb-0"><b>Important Safety Information</b></p>
      <p>Risankizumab is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.
Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection,
or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not
be initiated in patients with any clinically important active infection until the infection resolves or is adequately
treated. Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection.
Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be
considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate
course of treatment cannot be confirmed.</p>

<p>Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered
according to current immunisation guidelines. If a patient has received live vaccination (viral or bacterial),
it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with
risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.</p>

<p>The most frequently reported adverse reactions were upper respiratory infections, which occurred in 13% of patients.
Commonly (≥ <sup>1</sup>&frasl;<sub>100</sub> to &lt; <sup>1</sup>&frasl;<sub>10</sub>) reported adverse reactions included tinea infections, headache, pruritus, fatigue and
injection site reactions.</p>

<p>This is not a complete summary of all safety information. See SKYRIZI full summary of product characteristics (SmPC)
at <a href="https://www.ema.europa.eu/">www.ema.europa.eu</a>.</p>

    </div>
    <p><strong>ALL-SKZD-190006</strong></p>
  </div>

              </main>
            </div>
        </div>
    </div>

    
      


<script type="text/javascript" src="/js/jquery.min.js/"></script>
<script type="text/javascript" src="/js/popper.min.js/"></script>
<script type="text/javascript" src="/js/bootstrap.min.js/"></script>

<script type="text/javascript" src="/js/jquery-ui.js/"></script>

<script type="text/javascript" src="/js/site.min.js"></script>

    

  </body>
</html>
